| 2026 | Implementation of an alert system for the care cascade of Hepatitis C infection in patients undergoing elective surgery
| JOURNAL OF INFECTION AND PUBLIC HEALTH |
| 2026 | Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement
| CLINICAL AND MOLECULAR HEPATOLOGY |
| 2026 | Chronic Hepatitis B Infection: Patient Guidance
| JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
| 2025 | Head-to-head comparison between vibration-controlled transient elastography and histology in predicting liver-related events due to metabolic dysfunction-associated steatotic liver disease | HEPATOLOGY |
| 2025 | The Impact of Liraglutide on Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
| 2025 | Predictors of fibrosis, clinical events and mortality in MASLD: Data from the Global-MASLD study | HEPATOLOGY |
| 2025 | Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV-Related Cirrhosis: A Landmark Analysis
| JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
| 2025 | Response to the Letter Regarding "Incidence of Osteopenia or Osteoporosis in Asian Patients With Chronic Hepatitis B | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
| 2025 | Letter on 'Long-Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver-Related Events in Nucleos(t)ide Analogue-Treated Chronic Hepatitis B Patients in China' | ALIMENTARY PHARMACOLOGY & THERAPEUTICS |
| 2025 | Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study | HEPATOLOGY |
| 2025 | Association between longitudinal weight change and clinical outcome in individuals with MASLD | HEPATOLOGY |
| 2025 | Incidence and risk factors of hepatocellular carcinoma in patients with autoimmune hepatitis in Asia
| JHEP REPORTS |
| 2025 | Letter on "Immigration Factors and Monitoring of Chronic Hepatitis B Infection Among Foreign-Born: The FOCUS-HBV Multicentre Cohort"
| ALIMENTARY PHARMACOLOGY & THERAPEUTICS |
| 2025 | From “Burnt-Out” to “Burning-Out”: Capturing Liver Fat Loss in Patients With Advanced Metabolic Dysfunction–Associated Steatotic Liver Disease From a Dynamic Perspective | GASTROENTEROLOGY |
| 2025 | Besifovir dipivoxil maleate versus other antivirals in reducing hepatocellular carcinoma in chronic hepatitis B
| SCIENTIFIC REPORTS |
| 2025 | Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease | JOURNAL OF HEPATOLOGY |
| 2025 | Letter on "Association Between Viral Replication Activity and Postoperative Recurrence of HBV-Related Hepatocellular Carcinoma"
| ALIMENTARY PHARMACOLOGY & THERAPEUTICS |
| 2025 | Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease
| CLINICAL AND MOLECULAR HEPATOLOGY |
| 2025 | Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease | GUT |
| 2025 | Incidence of Osteopenia or Osteoporosis in Asian Patients With Chronic Hepatitis B | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
| 2025 | Noncontrast Magnetic Resonance Imaging vs Ultrasonography for Hepatocellular Carcinoma Surveillance: A Randomized, Single-Center Trial | GASTROENTEROLOGY |
| 2025 | Reply to: "Comment on "Lower incidence of hepatocellular carcinoma with tenofovir alafenamide in chronic hepatitis B: Evidence from a large-scale cohort
| JHEP REPORTS |
| 2025 | Risk of Variceal Bleeding in Patients Receiving Atezolizumab-Bevacizumab Treatment for Hepatocellular Carcinoma | ALIMENTARY PHARMACOLOGY & THERAPEUTICS |
| 2025 | Treatment of IL-18-binding protein biologics suppresses fibrotic progression in metabolic dysfunction-associated steatohepatitis
| CELL REPORTS MEDICINE |
| 2025 | acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study | CLINICAL GASTROENTEROLOGY AND HEPATOLOGY |
| 2025 | AI-Safe-C score: Assessing liver-related event risks in patients without cirrhosis after successful direct-acting antiviral treatment | JOURNAL OF HEPATOLOGY |
| 2025 | KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025
| CLINICAL AND MOLECULAR HEPATOLOGY |
| 2025 | Cytokine-Induced Killer Cell Immunotherapy Reduces Recurrence in Patients with Early-Stage Hepatocellular Carcinoma
| CANCERS |
| 2025 | Lower incidence of hepatocellular carcinoma with tenofovir alafenamide in chronic hepatitis B: Evidence from a large-scale cohort
| JHEP REPORTS |
| 2025 | Robust Predictive Performance of the SALT-M Score for Clinical Outcomes in Asian Patients With Acute-on-Chronic Liver Failure | ALIMENTARY PHARMACOLOGY & THERAPEUTICS |
| 2025 | Bacterial components-driven intrahepatic CXCR5hi B cells are important population for MASH progression through inducing inflammation | FASEB JOURNAL |
| 2025 | Intestinal TM6SF2 protects against metabolic dysfunction-associated steatohepatitis through the gut-liver axis
| NATURE METABOLISM |
| 2024 | Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions | NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY |
| 2024 | Incidence of metabolic dysfunction-associated steatotic liver disease and advanced fibrosis and impact of overweight/obesity in elderly population: a nationwide cohort study | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
| 2024 | Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease | GUT |
| 2024 | T-Cell Dynamics Predicts Prognosis of Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab
| INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES |
| 2024 | Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma
| YONSEI MEDICAL JOURNAL |
| 2024 | Prevalence and risk factors for impaired renal function among Asian patients with nonalcoholic fatty liver disease | HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL |
| 2024 | The associations between fibrosis changes and liver-related events in patients with metabolic dysfunction-associated steatotic liver disease | LIVER INTERNATIONAL |
| 2024 | Prevalence of nonalcoholic fatty liver disease in pediatrics and adolescents: a systematic review and meta-analysis | WORLD JOURNAL OF PEDIATRICS |
| 2024 | Hepatitis C virus infection in patients undergoing surgery in a single tertiary academic center | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
| 2024 | CAMP-B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance | ALIMENTARY PHARMACOLOGY & THERAPEUTICS |
| 2024 | Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease | JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION |
| 2024 | Neither hepatic steatosis nor fibrosis is associated with clinical outcomes in patients with intestinal Behçet’s disease | EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY |
| 2024 | A Liver Stiffness-Based Etiology-Independent Machine Learning Algorithm to Predict Hepatocellular Carcinoma | CLINICAL GASTROENTEROLOGY AND HEPATOLOGY |
| 2024 | Mobile App-Based Lifestyle Coaching Intervention for Patients With Nonalcoholic Fatty Liver Disease: Randomized Controlled Trial
| JOURNAL OF MEDICAL INTERNET RESEARCH |
| 2024 | Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Disease | GUT AND LIVER |
| 2023 | Unveiling and harnessing the human gut microbiome in the rising burden of non-communicable diseases during urbanization
| GUT MICROBES |
| 2023 | Fecal microbiota transplantation improves hepatic fibro-inflammation via regulating oxidative stress in experimental NASH
| DIGESTIVE AND LIVER DISEASE |
| 2023 | Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/β-catenin pathways in hepatocellular carcinoma
| CELL COMMUNICATION AND SIGNALING |
http://orcid.org/0000-0002-3552-3560
